ZA935111B
(en)
*
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
ZA935110B
(en)
*
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
USRE40596E1
(en)
*
|
1993-04-08 |
2008-12-02 |
Novartis Ag |
Rapamycin assay
|
GB9307491D0
(en)
|
1993-04-08 |
1993-06-02 |
Sandoz Ltd |
Organic compounds
|
JPH08509499A
(ja)
|
1993-04-23 |
1996-10-08 |
アボツト・ラボラトリーズ |
ラパマイシン結合体及び抗体
|
US7279561B1
(en)
*
|
1993-04-23 |
2007-10-09 |
Wyeth |
Anti-rapamycin monoclonal antibodies
|
USRE37421E1
(en)
|
1993-07-16 |
2001-10-23 |
Smithkline Beecham Corporation |
Rapamycin derivatives
|
ATE398448T1
(de)
*
|
1993-09-28 |
2008-07-15 |
Scherer Gmbh R P |
Herstellung von weichgelatinekapseln
|
WO1995014023A1
(en)
*
|
1993-11-19 |
1995-05-26 |
Abbott Laboratories |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
US5527907A
(en)
*
|
1993-11-19 |
1996-06-18 |
Abbott Laboratories |
Macrolide immunomodulators
|
DK0734389T3
(da)
*
|
1993-12-17 |
2000-08-21 |
Novartis Ag |
Rapamycinderivater, som er anvendelige som immunosuppressive midler
|
GB9405350D0
(en)
*
|
1994-03-18 |
1994-05-04 |
Sandoz Ltd |
Organic compounds
|
EP0786986B1
(de)
*
|
1994-10-26 |
2002-03-20 |
Novartis AG |
Verwendung eines ungesättigten Fettalkohols
|
US7205279B2
(en)
*
|
1995-10-25 |
2007-04-17 |
Novartis Ag |
Pharmaceutical compositions
|
IL115742A
(en)
|
1994-10-26 |
2000-06-01 |
Novartis Ag |
Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant
|
US5561138A
(en)
*
|
1994-12-13 |
1996-10-01 |
American Home Products Corporation |
Method of treating anemia
|
GB9618952D0
(en)
*
|
1996-09-11 |
1996-10-23 |
Sandoz Ltd |
Process
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
PT833828E
(pt)
*
|
1995-06-09 |
2003-02-28 |
Novartis Ag |
Derivados de rapamicina
|
FR2736550B1
(fr)
|
1995-07-14 |
1998-07-24 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
|
US5780462A
(en)
*
|
1995-12-27 |
1998-07-14 |
American Home Products Corporation |
Water soluble rapamycin esters
|
GB9601120D0
(en)
*
|
1996-01-19 |
1996-03-20 |
Sandoz Ltd |
Organic compounds
|
KR100616020B1
(ko)
*
|
1996-03-27 |
2007-01-31 |
노파르티스 아게 |
맥관장애및이종이식술에서의라파마이신유도체의용도
|
GB9606452D0
(en)
*
|
1996-03-27 |
1996-06-05 |
Sandoz Ltd |
Organic compounds
|
DK1208847T3
(da)
|
1996-07-30 |
2007-01-08 |
Novartis Ag |
Farmaceutiske præparater til behandling af transplantatafstödning samt autoimmune eller inflammatoriske tilstande
|
JP2001500126A
(ja)
*
|
1996-09-09 |
2001-01-09 |
アメリカン・ホーム・プロダクツ・コーポレイション |
アルキル化ラパマイシン誘導体
|
US5922730A
(en)
*
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
GB9624038D0
(en)
*
|
1996-11-19 |
1997-01-08 |
Sandoz Ltd |
Organic compounds
|
US6306166B1
(en)
*
|
1997-08-13 |
2001-10-23 |
Scimed Life Systems, Inc. |
Loading and release of water-insoluble drugs
|
MEP30008A
(en)
*
|
1998-03-26 |
2010-10-10 |
Astellas Pharma Inc |
Sustained release preparations
|
US20050031611A1
(en)
*
|
1998-05-08 |
2005-02-10 |
Beth Israel Deaconess Medical Center |
Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
|
DK1105395T3
(da)
*
|
1998-08-17 |
2002-10-14 |
Wyeth Corp |
Fotoringsluttede rapamyciner
|
US6015809A
(en)
*
|
1998-08-17 |
2000-01-18 |
American Home Products Corporation |
Photocyclized rapamycin
|
GB9826882D0
(en)
*
|
1998-12-07 |
1999-01-27 |
Novartis Ag |
Organic compounds
|
US7276506B2
(en)
*
|
1998-12-28 |
2007-10-02 |
4 Aza Bioscience Nv |
Immunosuppressive effects of pteridine derivatives
|
US6946465B2
(en)
*
|
1999-02-02 |
2005-09-20 |
4 Aza Bioscience Nv |
Immunosuppressive effects of pteridine derivatives
|
US7063857B1
(en)
|
1999-04-30 |
2006-06-20 |
Sucampo Ag |
Use of macrolide compounds for the treatment of dry eye
|
EP1980263A1
(de)
|
1999-05-10 |
2008-10-15 |
Novartis AG |
Kombinationen von immunsuppressiven Mitteln zur Behandlung bzw. Prävention von Transplantatabstoßungen
|
JP2003507382A
(ja)
*
|
1999-08-18 |
2003-02-25 |
ワイス |
水溶性sdz−radエステル
|
US6331547B1
(en)
|
1999-08-18 |
2001-12-18 |
American Home Products Corporation |
Water soluble SDZ RAD esters
|
IL147803A0
(en)
|
1999-08-24 |
2002-08-14 |
Ariad Gene Therapeutics Inc |
28-epirapalogs
|
US7067526B1
(en)
|
1999-08-24 |
2006-06-27 |
Ariad Gene Therapeutics, Inc. |
28-epirapalogs
|
US7807211B2
(en)
|
1999-09-03 |
2010-10-05 |
Advanced Cardiovascular Systems, Inc. |
Thermal treatment of an implantable medical device
|
US6790228B2
(en)
|
1999-12-23 |
2004-09-14 |
Advanced Cardiovascular Systems, Inc. |
Coating for implantable devices and a method of forming the same
|
US20070032853A1
(en)
*
|
2002-03-27 |
2007-02-08 |
Hossainy Syed F |
40-O-(2-hydroxy)ethyl-rapamycin coated stent
|
US6277983B1
(en)
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
EP2298299A3
(de)
*
|
2000-01-14 |
2012-02-29 |
The Trustees Of The University Of Pennsylvania |
O-methylierte Rapamycinderivate zur Linderung und Verhinderung von lymphoproliferativen Erkrankungen
|
GB0008785D0
(en)
|
2000-04-10 |
2000-05-31 |
Novartis Ag |
Organic compounds
|
US8236048B2
(en)
|
2000-05-12 |
2012-08-07 |
Cordis Corporation |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US6670355B2
(en)
*
|
2000-06-16 |
2003-12-30 |
Wyeth |
Method of treating cardiovascular disease
|
US6511986B2
(en)
|
2000-08-11 |
2003-01-28 |
Wyeth |
Method of treating estrogen receptor positive carcinoma
|
DK1319008T3
(da)
|
2000-09-19 |
2009-02-09 |
Wyeth Corp |
Vandoplöselige rapamycinestere
|
US6399625B1
(en)
*
|
2000-09-27 |
2002-06-04 |
Wyeth |
1-oxorapamycins
|
WO2002026139A1
(en)
|
2000-09-29 |
2002-04-04 |
Cordis Corporation |
Coated medical devices
|
US6440991B1
(en)
*
|
2000-10-02 |
2002-08-27 |
Wyeth |
Ethers of 7-desmethlrapamycin
|
US6399626B1
(en)
|
2000-10-02 |
2002-06-04 |
Wyeth |
Hydroxyesters of 7-desmethylrapamycin
|
PT1415987E
(pt)
|
2000-10-20 |
2007-05-31 |
Eisai R&D Man Co Ltd |
Compostos contendo aneis aromáticos azotados utilizados como agentes anti-cancerígenos.
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
JP2004525899A
(ja)
|
2001-02-19 |
2004-08-26 |
ノバルティス アクチエンゲゼルシャフト |
癌の処置
|
AU2005201004A1
(en)
*
|
2001-02-19 |
2005-03-24 |
Novartis Ag |
Cancer treatment
|
AU2011226833B9
(en)
*
|
2001-02-19 |
2014-07-03 |
Novartis Ag |
Cancer treatment
|
AU2016206379B2
(en)
*
|
2001-02-19 |
2017-09-14 |
Novartis Ag |
Cancer Treatment
|
TWI296196B
(en)
*
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
TWI233359B
(en)
*
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
CA2452372A1
(en)
|
2001-07-06 |
2003-01-16 |
Sucampo Ag |
Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
|
EP1554572B1
(de)
|
2001-07-25 |
2009-10-14 |
Raptor Pharmaceutical Inc. |
Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
|
US6939376B2
(en)
*
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US7682387B2
(en)
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
EP1458405A1
(de)
*
|
2001-11-21 |
2004-09-22 |
Sucampo AG |
Verwendung von fk506 und analoga zur behandlung von allergischen erkrankungen
|
PL216224B1
(pl)
*
|
2002-02-01 |
2014-03-31 |
Ariad Pharmaceuticals |
Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie
|
US20030176455A1
(en)
*
|
2002-03-13 |
2003-09-18 |
Wyeth |
Method of inhibiting cell death
|
US20040024450A1
(en)
*
|
2002-04-24 |
2004-02-05 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
BR0311173A
(pt)
|
2002-05-16 |
2005-03-15 |
Novartis Ag |
Uso de agentes de ligação do receptor de edg em câncer
|
EP1521828B1
(de)
|
2002-07-16 |
2015-07-01 |
Buck Institute for Research on Aging |
Herstellung von polyketiden
|
AR040693A1
(es)
|
2002-07-30 |
2005-04-13 |
Wyeth Corp |
Formulaciones parenterales
|
EP1539157B1
(de)
*
|
2002-09-18 |
2013-08-21 |
Trustees Of The University Of Pennsylvania |
Rapamycin zur Verwendung in der Hemmung oder Vorbeugung der choroidalen Neovaskularisation
|
RU2478378C2
(ru)
|
2002-09-24 |
2013-04-10 |
Новартис Аг |
Органические соединения
|
WO2004060283A2
(en)
|
2002-12-16 |
2004-07-22 |
Nitromed, Inc. |
Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
|
JP2006516548A
(ja)
|
2002-12-30 |
2006-07-06 |
アンジオテック インターナショナル アクツィエン ゲゼルシャフト |
迅速ゲル化ポリマー組成物からの薬物送達法
|
AR042938A1
(es)
*
|
2003-02-06 |
2005-07-06 |
Wyeth Corp |
Uso del cci-779 en el tratamiento de la fibrosis hepatica
|
US20090093875A1
(en)
|
2007-05-01 |
2009-04-09 |
Abbott Laboratories |
Drug eluting stents with prolonged local elution profiles with high local concentrations and low systemic concentrations
|
AR043504A1
(es)
*
|
2003-03-17 |
2005-08-03 |
Novartis Ag |
Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
|
GB0307867D0
(en)
*
|
2003-04-04 |
2003-05-14 |
Novartis Ag |
Pharmaceutical composition
|
WO2004089369A2
(en)
*
|
2003-04-11 |
2004-10-21 |
Cambridge University Technical Services Limited |
Methods and means for treating protein conformational disorders
|
MXPA05010582A
(es)
*
|
2003-04-22 |
2005-11-23 |
Wyeth Corp |
Combinaciones antineoplasicas.
|
US7160867B2
(en)
*
|
2003-05-16 |
2007-01-09 |
Isotechnika, Inc. |
Rapamycin carbohydrate derivatives
|
US20050118344A1
(en)
|
2003-12-01 |
2005-06-02 |
Pacetti Stephen D. |
Temperature controlled crimping
|
CA2531454C
(en)
*
|
2003-07-08 |
2011-10-25 |
Novartis Ag |
Use of rapamycin and rapamycin derivatives for the treatment of bone loss
|
ES2293324T3
(es)
*
|
2003-09-12 |
2008-03-16 |
4 Aza Ip Nv |
Derivados de pteridina para el tratamiento de enfermedades relativas al tnf-alpha.
|
CA2539324A1
(en)
|
2003-09-18 |
2005-03-31 |
Macusight, Inc. |
Transscleral delivery
|
US20070032477A1
(en)
*
|
2003-10-17 |
2007-02-08 |
Waer Mark J A |
Pteridine derivatives useful for making pharmaceutical compositions
|
US7220755B2
(en)
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
US9114198B2
(en)
|
2003-11-19 |
2015-08-25 |
Advanced Cardiovascular Systems, Inc. |
Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
|
GB0327840D0
(en)
*
|
2003-12-01 |
2003-12-31 |
Novartis Ag |
Organic compounds
|
ES2315745T3
(es)
*
|
2004-03-01 |
2009-04-01 |
Terumo Kabushiki Kaisha |
Procedimiento para la fabricacion de derivados o-alquilados de rapamicina.
|
JP4716280B2
(ja)
*
|
2004-03-01 |
2011-07-06 |
テルモ株式会社 |
O−アルキル化ラパマイシン誘導体の製造法
|
US20050208607A1
(en)
|
2004-03-10 |
2005-09-22 |
Mark Roberts |
Immunoassays for everolimus
|
AR047988A1
(es)
*
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
US8551512B2
(en)
*
|
2004-03-22 |
2013-10-08 |
Advanced Cardiovascular Systems, Inc. |
Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
|
US8778014B1
(en)
|
2004-03-31 |
2014-07-15 |
Advanced Cardiovascular Systems, Inc. |
Coatings for preventing balloon damage to polymer coated stents
|
AU2005238432A1
(en)
*
|
2004-04-14 |
2005-11-10 |
Wyeth |
Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
|
EP1740710A1
(de)
*
|
2004-04-27 |
2007-01-10 |
Wyeth |
Markierung von rapamycin mit rapamycinspezifischen methylasen
|
EP1768662A2
(de)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Immunstimulatoren kleiner moleküle und assays für deren nachweis
|
US8709469B2
(en)
|
2004-06-30 |
2014-04-29 |
Abbott Cardiovascular Systems Inc. |
Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
|
GB0417852D0
(en)
|
2004-08-11 |
2004-09-15 |
Biotica Tech Ltd |
Production of polyketides and other natural products
|
ATE483716T1
(de)
|
2004-08-27 |
2010-10-15 |
Cordis Corp |
Lösungsmittelfreies amorphes rapamycin
|
EP1797881B1
(de)
|
2004-09-17 |
2009-04-15 |
Eisai R&D Management Co., Ltd. |
Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
|
US7901451B2
(en)
|
2004-09-24 |
2011-03-08 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US8313763B2
(en)
|
2004-10-04 |
2012-11-20 |
Tolmar Therapeutics, Inc. |
Sustained delivery formulations of rapamycin compounds
|
WO2006041942A2
(en)
*
|
2004-10-04 |
2006-04-20 |
Qlt Usa, Inc. |
Ocular delivery of polymeric delivery formulations
|
WO2006050461A1
(en)
*
|
2004-10-28 |
2006-05-11 |
Wyeth |
Use of an mtor inhibitor in treatment of uterine leiomyoma
|
US8021849B2
(en)
|
2004-11-05 |
2011-09-20 |
Siemens Healthcare Diagnostics Inc. |
Methods and kits for the determination of sirolimus in a sample
|
WO2006053754A1
(en)
*
|
2004-11-19 |
2006-05-26 |
Novartis Ag |
COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
|
US20060160837A1
(en)
*
|
2004-12-29 |
2006-07-20 |
The Brigham And Women's Hospital, Inc. |
Rapamycin compounds in the treatment of neurofibromatosis type 1
|
PL1848431T3
(pl)
|
2005-02-09 |
2016-08-31 |
Santen Pharmaceutical Co Ltd |
Ciekłe formulacje do leczenia chorób lub stanów
|
US8663639B2
(en)
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
GB0503936D0
(en)
|
2005-02-25 |
2005-04-06 |
San Raffaele Centro Fond |
Method
|
US20100047338A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
GB0504544D0
(en)
|
2005-03-04 |
2005-04-13 |
Novartis Ag |
Organic compounds
|
CN101137659A
(zh)
|
2005-03-07 |
2008-03-05 |
惠氏公司 |
42-o-(2-羟基)乙基-雷帕霉素的氧杂环庚烷异构体
|
GB0504994D0
(en)
*
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
CA2599547A1
(en)
|
2005-03-11 |
2006-09-14 |
Biotica Technology Limited |
Medical uses of 39-desmethoxyrapamycin and analogues thereof
|
US20100061994A1
(en)
*
|
2005-03-11 |
2010-03-11 |
Rose Mary Sheridan |
Medical uses of 39-desmethoxyrapamycin and analogues thereof
|
GT200600148A
(es)
*
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
US7189582B2
(en)
|
2005-04-27 |
2007-03-13 |
Dade Behring Inc. |
Compositions and methods for detection of sirolimus
|
AU2006239221C1
(en)
|
2005-04-28 |
2012-08-16 |
Otsuka Pharmaceutical Co., Ltd. |
Pharma-informatics system
|
EP1890728A1
(de)
*
|
2005-05-31 |
2008-02-27 |
Novartis AG |
Kombination aus hmg-coa-reduktasehemmern und mtor-hemmern
|
US20070004767A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Gutmann David H |
Methods for treating neurofibromatosis 1
|
WO2007011707A2
(en)
|
2005-07-15 |
2007-01-25 |
Micell Technologies, Inc. |
Polymer coatings containing drug powder of controlled morphology
|
US20090062909A1
(en)
|
2005-07-15 |
2009-03-05 |
Micell Technologies, Inc. |
Stent with polymer coating containing amorphous rapamycin
|
AU2006271650B8
(en)
|
2005-07-20 |
2011-02-10 |
Novartis Ag |
Combination of a pyrimidylaminobenzamide and an mTOR kinase inhibitor
|
CN101282745B
(zh)
|
2005-07-25 |
2015-04-29 |
新兴产品开发西雅图有限公司 |
用cd37-特异性和cd20-特异性结合分子减少b-细胞
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
AU2006284922B2
(en)
|
2005-08-30 |
2012-01-19 |
University Of Miami |
Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
|
EP1776970A1
(de)
|
2005-10-12 |
2007-04-25 |
Albert Schömig |
Implantat mit Mehrfachbeschichtung
|
WO2007056118A1
(en)
|
2005-11-04 |
2007-05-18 |
Wyeth |
Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
|
GB0523659D0
(en)
*
|
2005-11-21 |
2005-12-28 |
Novartis Ag |
Organic compounds
|
WO2007075621A1
(en)
*
|
2005-12-20 |
2007-07-05 |
Wyeth |
Control of cci-779 dosage form stability through control of drug substance impurities
|
EP1976530A1
(de)
*
|
2006-01-12 |
2008-10-08 |
Novartis AG |
Kombination aus einem mtor-hemmer und einer antipolat-zusammensetzung
|
US20070173923A1
(en)
*
|
2006-01-20 |
2007-07-26 |
Savage Douglas R |
Drug reservoir stent
|
GB0601406D0
(en)
*
|
2006-01-24 |
2006-03-08 |
Novartis Ag |
Organic Compounds
|
CA2637255C
(en)
*
|
2006-02-02 |
2018-06-12 |
Novartis Ag |
40-o-(2-hydroxyethyl)-rapamycin for treating tuberous sclerosis disorders
|
JP5528708B2
(ja)
|
2006-02-09 |
2014-06-25 |
参天製薬株式会社 |
安定な製剤ならびにそれらを調製および使用する方法
|
US7622477B2
(en)
*
|
2006-02-28 |
2009-11-24 |
Cordis Corporation |
Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
|
US7678901B2
(en)
*
|
2006-02-28 |
2010-03-16 |
Wyeth |
Rapamycin analogs containing an antioxidant moiety
|
CA2644156A1
(en)
*
|
2006-03-07 |
2007-09-13 |
Wyeth |
Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants
|
CA2645488C
(en)
|
2006-03-23 |
2014-09-02 |
Macusight, Inc. |
Formulations comprising rapamycin and methods using same for vascular permeability-related diseases or conditions
|
WO2007127363A2
(en)
|
2006-04-26 |
2007-11-08 |
Micell Technologies, Inc. |
Coatings containing multiple drugs
|
CA2652442C
(en)
|
2006-05-18 |
2014-12-09 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
GB0609963D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
GB0609962D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
CA2656112A1
(en)
*
|
2006-06-30 |
2008-05-08 |
Hanje Chen |
Bioresponsive polymers
|
WO2008009078A2
(en)
|
2006-07-20 |
2008-01-24 |
Gilead Sciences, Inc. |
4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
|
WO2008009079A2
(en)
*
|
2006-07-20 |
2008-01-24 |
Gilead Sciences, Inc. |
Substituted pteridines useful for the treatment and prevention of viral infections
|
WO2008016633A2
(en)
*
|
2006-08-02 |
2008-02-07 |
Ariad Gene Therapeutics, Inc. |
Combination therapy
|
KR101472600B1
(ko)
|
2006-08-28 |
2014-12-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암에 대한 항종양제
|
US20080051691A1
(en)
*
|
2006-08-28 |
2008-02-28 |
Wyeth |
Implantable shunt or catheter enabling gradual delivery of therapeutic agents
|
US8088789B2
(en)
|
2006-09-13 |
2012-01-03 |
Elixir Medical Corporation |
Macrocyclic lactone compounds and methods for their use
|
CN104906087A
(zh)
*
|
2006-09-13 |
2015-09-16 |
万能医药公司 |
大环内酯化合物及它们的使用方法
|
US10695327B2
(en)
|
2006-09-13 |
2020-06-30 |
Elixir Medical Corporation |
Macrocyclic lactone compounds and methods for their use
|
WO2008036682A2
(en)
|
2006-09-18 |
2008-03-27 |
Raptor Pharmaceutical Inc. |
Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
|
US20080097591A1
(en)
|
2006-10-20 |
2008-04-24 |
Biosensors International Group |
Drug-delivery endovascular stent and method of use
|
US8067055B2
(en)
*
|
2006-10-20 |
2011-11-29 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method of use
|
WO2008065887A1
(fr)
|
2006-11-27 |
2008-06-05 |
Terumo Kabushiki Kaisha |
Procédé de fabrication d'un dérivé de rapamycine o-alkylé, et dérivé de rapamycine o-alkylée
|
WO2008086369A1
(en)
|
2007-01-08 |
2008-07-17 |
Micell Technologies, Inc. |
Stents having biodegradable layers
|
US11426494B2
(en)
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
WO2008086794A2
(de)
|
2007-01-21 |
2008-07-24 |
Hemoteq Ag |
Medizinprodukt zur behandlung von verschlüssen von körperdurchgängen und zur prävention drohender wiederverschlüsse
|
CA2676796C
(en)
|
2007-01-29 |
2016-02-23 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
TW200845960A
(en)
*
|
2007-04-05 |
2008-12-01 |
Wyeth Corp |
Wortmannin-rapalog conjugate and uses thereof
|
TW200901989A
(en)
*
|
2007-04-10 |
2009-01-16 |
Wyeth Corp |
Anti-tumor activity of CCI-779 in papillary renal cell cancer
|
US9192697B2
(en)
|
2007-07-03 |
2015-11-24 |
Hemoteq Ag |
Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
|
WO2009043174A1
(en)
|
2007-10-05 |
2009-04-09 |
Interface Biologics Inc. |
Oligofluorinated cross-linked polymers and uses thereof
|
WO2009049426A1
(en)
|
2007-10-19 |
2009-04-23 |
Interface Biologics Inc. |
Self-eliminating coatings
|
US8952035B2
(en)
|
2007-11-09 |
2015-02-10 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
CN103480047B
(zh)
|
2007-11-14 |
2015-02-18 |
生物传感器国际集团有限公司 |
自动化涂覆设备和方法
|
US8921642B2
(en)
*
|
2008-01-11 |
2014-12-30 |
Massachusetts Eye And Ear Infirmary |
Conditional-stop dimerizable caspase transgenic animals
|
CN102215682A
(zh)
*
|
2008-03-11 |
2011-10-12 |
万能医药公司 |
大环内酯化合物及它们的使用方法
|
JP5647098B2
(ja)
|
2008-03-21 |
2014-12-24 |
ザ ユニヴァーシティー オヴ シカゴ |
オピオイド拮抗薬とmTOR阻害薬を用いた治療
|
NZ603059A
(en)
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
US20110098241A1
(en)
*
|
2008-04-14 |
2011-04-28 |
Poniard Pharmaceuticals, Inc. |
Rapamycin analogs as anti-cancer agents
|
EP3360586B1
(de)
|
2008-04-17 |
2024-03-06 |
Micell Technologies, Inc. |
Stents mit biologisch abbaubaren schichten
|
EP2303250A1
(de)
|
2008-06-20 |
2011-04-06 |
Novartis AG |
Pädiatrische zusammensetzungen zur behandlung von multipler sklerose
|
US8765162B2
(en)
|
2008-06-30 |
2014-07-01 |
Abbott Cardiovascular Systems Inc. |
Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
|
US9510856B2
(en)
|
2008-07-17 |
2016-12-06 |
Micell Technologies, Inc. |
Drug delivery medical device
|
WO2010009335A1
(en)
|
2008-07-17 |
2010-01-21 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US8092822B2
(en)
|
2008-09-29 |
2012-01-10 |
Abbott Cardiovascular Systems Inc. |
Coatings including dexamethasone derivatives and analogs and olimus drugs
|
KR20110074758A
(ko)
*
|
2008-10-03 |
2011-07-01 |
엘릭서 메디컬 코포레이션 |
마크로사이클릭 락톤 화합물 및 이를 사용하는 방법
|
EP2337788B1
(de)
|
2008-10-17 |
2016-03-23 |
Wisconsin Alumni Research Foundation |
Verfahren zur herstellung biologisch aktiver alpha-beta-peptide
|
DK2365802T3
(da)
|
2008-11-11 |
2017-11-13 |
Univ Texas |
Mikrokapsler af rapamycin og anvendelse til behandling af cancer
|
CN102753563A
(zh)
|
2008-12-23 |
2012-10-24 |
吉利德制药有限责任公司 |
核苷类似物
|
WO2010075554A1
(en)
|
2008-12-23 |
2010-07-01 |
Pharmasset, Inc. |
Synthesis of purine nucleosides
|
PA8855601A1
(es)
|
2008-12-23 |
2010-07-27 |
|
Forformidatos de nucleósidos
|
JP5643770B2
(ja)
*
|
2009-01-21 |
2014-12-17 |
バイオコン・リミテッドBiocon Limited |
シロリムスの安定性の決定方法およびその安定形態の調製方法
|
JP2012516900A
(ja)
|
2009-02-05 |
2012-07-26 |
トーカイ ファーマシューティカルズ,インク. |
ステロイド性cyp17阻害剤/抗アンドロゲン剤の新しいプロドラッグ
|
US8901132B2
(en)
|
2009-03-13 |
2014-12-02 |
Katholieke Universiteit Leuven, K.U. Leuven R&D |
Thiazolopyrimidine modulators as immunosuppressive agents
|
CN102481195B
(zh)
|
2009-04-01 |
2015-03-25 |
米歇尔技术公司 |
涂覆支架
|
WO2010120599A2
(en)
|
2009-04-16 |
2010-10-21 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
EP2419058B1
(de)
|
2009-04-17 |
2018-02-28 |
Micell Technologies, Inc. |
Stents mit gesteuerter elution
|
KR101741629B1
(ko)
|
2009-05-06 |
2017-05-31 |
라보라토리 스킨 케어, 인크. |
활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
|
EP2944332B1
(de)
|
2009-07-10 |
2016-08-17 |
Boston Scientific Scimed, Inc. |
Verwendung von nanokristallen für einen wirkstofffreisetzungsballon
|
EP2453938B1
(de)
|
2009-07-17 |
2015-08-19 |
Boston Scientific Scimed, Inc. |
Nukleierung von wirkstofffreisetzungsballons für verbesserte kristallgrösse und -dichte
|
JP2013501057A
(ja)
|
2009-08-03 |
2013-01-10 |
ユニバーシティー・オブ・マイアミ |
制御性t細胞のinvivoにおける増殖
|
EA020151B1
(ru)
|
2009-10-23 |
2014-09-30 |
Эли Лилли Энд Компани |
Ингибиторы akt и фармацевтические составы, их содержащие
|
CN102770129A
(zh)
|
2009-10-30 |
2012-11-07 |
阿里亚德医药股份有限公司 |
治疗癌症的方法和组合物
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
US20170079962A1
(en)
|
2009-11-11 |
2017-03-23 |
Rapamycin Holdings, Llc |
Oral Rapamycin Preparation and Use for Stomatitus
|
KR20120107962A
(ko)
|
2009-11-18 |
2012-10-04 |
노파르티스 아게 |
고형 종양 및 다른 악성종양의 치료를 위한 방법 및 조성물
|
WO2011072398A1
(en)
|
2009-12-18 |
2011-06-23 |
Interface Biologics, Inc. |
Local delivery of drugs from self assembled coatings
|
CN102127092B
(zh)
*
|
2010-01-18 |
2013-04-17 |
东南大学 |
依维莫斯的制备
|
WO2011097103A1
(en)
|
2010-02-02 |
2011-08-11 |
Micell Technologies, Inc. |
Stent and stent delivery system with improved deliverability
|
US20130195919A1
(en)
|
2010-03-05 |
2013-08-01 |
President And Fellows Of Harvard College |
Induced dendritic cell compositions and uses thereof
|
JP6058528B2
(ja)
|
2010-03-31 |
2017-01-11 |
ギリアド ファーマセット エルエルシー |
ヌクレオシドホスホルアミデート
|
CN102869358B
(zh)
|
2010-04-13 |
2016-03-23 |
诺华股份有限公司 |
用于治疗癌症的包含细胞周期蛋白依赖性激酶4或细胞周期蛋白依赖性激酶6(CDK4/6)抑制剂和mTOR抑制剂的组合
|
RU2012148706A
(ru)
|
2010-04-16 |
2014-05-27 |
Новартис Аг |
Комбинация органичемких соединений
|
CA2797110C
(en)
|
2010-04-22 |
2020-07-21 |
Micell Technologies, Inc. |
Stents and other devices having extracellular matrix coating
|
KR101620661B1
(ko)
|
2010-04-27 |
2016-05-12 |
로슈 글리카트 아게 |
어푸코실화된 CD20 항체와 mTOR 억제제의 복합 요법
|
GB201012889D0
(en)
|
2010-08-02 |
2010-09-15 |
Univ Leuven Kath |
Antiviral activity of novel bicyclic heterocycles
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
WO2012009684A2
(en)
|
2010-07-16 |
2012-01-19 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US8889211B2
(en)
|
2010-09-02 |
2014-11-18 |
Boston Scientific Scimed, Inc. |
Coating process for drug delivery balloons using heat-induced rewrap memory
|
GB201015411D0
(en)
|
2010-09-15 |
2010-10-27 |
Univ Leuven Kath |
Anti-cancer activity of novel bicyclic heterocycles
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
CN102464669B
(zh)
*
|
2010-11-17 |
2014-04-16 |
浙江海正药业股份有限公司 |
无定形依维莫司及其制备方法
|
US9079921B2
(en)
*
|
2010-11-19 |
2015-07-14 |
Biocon Limited |
Processes for preparation of Everolimus and intermediates thereof
|
EP4053133A1
(de)
|
2011-02-04 |
2022-09-07 |
Synthon B.V. |
Verfahren zum herstellen von trisubstituierten silyloxyethyl-triflaten
|
ES2547916T3
(es)
|
2011-02-18 |
2015-10-09 |
Novartis Pharma Ag |
Terapia de combinación de inhibidores de mTOR/JAK
|
CN102174053B
(zh)
*
|
2011-03-09 |
2014-04-16 |
成都雅途生物技术有限公司 |
依维莫司的纯化方法
|
SI2683406T1
(sl)
|
2011-03-11 |
2019-10-30 |
Beth Israel Deconess Medical Center Inc |
Protitelesa ANTI-CD40 in njihova uporaba
|
EP2508525A1
(de)
|
2011-04-05 |
2012-10-10 |
Bayer Pharma Aktiengesellschaft |
Substituierte 2,3-Dihydroimidazo[1,2-c]chinazolinsalze
|
BR112013021941B1
(pt)
|
2011-04-18 |
2022-11-16 |
Eisai R & D Management Co., Ltd |
Agente terapêutico para tumor
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
NZ615593A
(en)
|
2011-04-25 |
2015-05-29 |
Novartis Ag |
Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
|
EP3444363B1
(de)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
|
EP2717884A1
(de)
|
2011-06-06 |
2014-04-16 |
Chevron Phillips Chemical Company LP |
Verwendung von metallocenverbindungen zur krebsbehandlung
|
EP2532740A1
(de)
|
2011-06-11 |
2012-12-12 |
Michael Schmück |
Antigenspezifische CD4+ und CD8+ zentrale Gedächtnis-T-Zellpräparate für adoptive T-Zelltherapie
|
WO2013012689A1
(en)
|
2011-07-15 |
2013-01-24 |
Micell Technologies, Inc. |
Drug delivery medical device
|
WO2013013708A1
(en)
|
2011-07-26 |
2013-01-31 |
Fundació Institut D'investigació Biomèdica De Bellvitge |
Treatment of acute rejection in renal transplant
|
US20130028895A1
(en)
|
2011-07-27 |
2013-01-31 |
Gerald Wulf |
Exosome inhibiting agents and uses thereof
|
US8669360B2
(en)
|
2011-08-05 |
2014-03-11 |
Boston Scientific Scimed, Inc. |
Methods of converting amorphous drug substance into crystalline form
|
US9056152B2
(en)
|
2011-08-25 |
2015-06-16 |
Boston Scientific Scimed, Inc. |
Medical device with crystalline drug coating
|
CN102268015B
(zh)
*
|
2011-08-30 |
2013-08-28 |
成都摩尔生物医药有限公司 |
一种依维莫司的合成方法
|
GB201115665D0
(en)
|
2011-09-09 |
2011-10-26 |
Univ Leuven Kath |
Autoimmune and inflammatory disorder therapy
|
US20140242162A1
(en)
|
2011-10-06 |
2014-08-28 |
Novartis Ag |
Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin
|
US10188772B2
(en)
|
2011-10-18 |
2019-01-29 |
Micell Technologies, Inc. |
Drug delivery medical device
|
EP2589383A1
(de)
|
2011-11-06 |
2013-05-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
FKBP-subtypspezifisches Rapamycin-Analogon zur Verwendung bei der Behandlung von Erkrankungen
|
GB201122305D0
(en)
|
2011-12-23 |
2012-02-01 |
Biotica Tech Ltd |
Novel compound
|
RU2014149145A
(ru)
|
2012-05-23 |
2016-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Композиции и способы получения и применения эндодермальных клеток и гепатоцитов
|
CN102786534A
(zh)
*
|
2012-05-25 |
2012-11-21 |
上海现代制药股份有限公司 |
一种依维莫司的制备方法
|
CA2869102C
(en)
|
2012-06-08 |
2019-02-26 |
Biotronik Ag |
Rapamycin 40-o-cyclic hydrocarbon esters, compositions and methods
|
WO2013192367A1
(en)
|
2012-06-22 |
2013-12-27 |
Novartis Ag |
Neuroendocrine tumor treatment
|
CN103705925B
(zh)
|
2012-09-29 |
2018-03-30 |
段磊 |
抑制PI3K/AKT/mTOR信号通路的药物组合
|
US9750728B2
(en)
|
2012-09-29 |
2017-09-05 |
Targeted Therapeutics, Llc |
Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
|
CA2926747A1
(en)
|
2012-10-12 |
2014-04-17 |
Arlan RICHARDSON |
Use of mtor inhibitors to treat vascular cognitive impairment
|
US20150258127A1
(en)
|
2012-10-31 |
2015-09-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
WO2014078522A1
(en)
|
2012-11-14 |
2014-05-22 |
Ohio State Innovation Foundation |
Materials and methods useful for treating glioblastoma
|
EP2809675A4
(de)
*
|
2012-11-30 |
2015-08-12 |
Hangzhou Zylox Pharma Co Ltd |
Rafamycin-analoga und verfahren zur herstellung davon
|
CA2889866A1
(en)
|
2012-12-21 |
2014-06-26 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
KR20210041631A
(ko)
|
2013-01-09 |
2021-04-15 |
유니버시티 오브 마이애미 |
TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
|
EP2967803B1
(de)
|
2013-03-12 |
2023-12-27 |
Micell Technologies, Inc. |
Bioabsorbierbare biomedizinische implantate
|
DK2968281T3
(da)
|
2013-03-13 |
2020-11-02 |
Univ Texas |
Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
|
WO2014153215A1
(en)
|
2013-03-14 |
2014-09-25 |
University Of Maryland,Baltimore Office Of Technology Transfer |
Androgen receptor down-regulating agents and uses thereof
|
US10098871B2
(en)
|
2013-03-15 |
2018-10-16 |
Leslie B. Gordon |
Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
|
TW201503912A
(zh)
|
2013-03-19 |
2015-02-01 |
Novartis Ag |
包含癌莫事(everolimus)之醫藥組合物
|
EP2994758B1
(de)
|
2013-05-08 |
2017-12-20 |
Opthea Limited |
Biomarker für altersbedingte makuladegeneration (amd)
|
CN105264380B
(zh)
|
2013-05-14 |
2017-09-05 |
卫材R&D管理有限公司 |
用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
|
CN105377318A
(zh)
|
2013-05-15 |
2016-03-02 |
脉胜医疗技术公司 |
可生物吸收的生物医学植入物
|
US9593356B2
(en)
|
2013-06-11 |
2017-03-14 |
Takara Bio Usa, Inc. |
Protein enriched microvesicles and methods of making and using the same
|
EP3010926B1
(de)
*
|
2013-06-20 |
2019-11-20 |
Novartis AG |
Alkylierung mit einem alkyl fluoroalkylsulfonat
|
CN103360411B
(zh)
*
|
2013-07-17 |
2015-09-30 |
成都雅途生物技术有限公司 |
依维莫司结晶提纯方法
|
AU2014306698A1
(en)
|
2013-08-12 |
2016-01-28 |
Tokai Pharmaceuticals, Inc. |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
US9580758B2
(en)
|
2013-11-12 |
2017-02-28 |
Luc Montagnier |
System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
|
WO2015073644A1
(en)
|
2013-11-13 |
2015-05-21 |
Novartis Ag |
Mtor inhibitors for enhancing the immune response
|
WO2015090230A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
KR101529963B1
(ko)
*
|
2013-12-27 |
2015-06-19 |
주식회사 종근당바이오 |
에베로리무스의 제조방법 및 이의 중간체
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
DK3089737T3
(da)
|
2013-12-31 |
2021-12-13 |
Rapamycin Holdings Llc |
Orale rapamycin-nanopartikelpræparater og anvendelse.
|
WO2015108912A1
(en)
|
2014-01-16 |
2015-07-23 |
MUSC Foundation for Research and Development |
Targeted nanocarriers for the administration of immunosuppressive agents
|
BR112016014903A8
(pt)
|
2014-02-11 |
2018-05-02 |
Novartis Ag |
combinações farmacêuticas que compreendem um inibidor de pi3k, seu uso, sua preparação combinada, e embalagem comercial
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
WO2015142661A1
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
CN103848849B
(zh)
*
|
2014-03-24 |
2016-02-24 |
上海医药工业研究院 |
依维莫司的制备工艺
|
EP3122376A4
(de)
|
2014-03-27 |
2017-12-20 |
The Brigham and Women's Hospital, Inc. |
Metabolisch aktivierte wirkstoffkonjugate zur überwindung der resistenz in der krebstherapie
|
PL3129470T3
(pl)
|
2014-04-07 |
2021-11-29 |
Novartis Ag |
Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
|
WO2015171723A1
(en)
|
2014-05-06 |
2015-11-12 |
Research Development Foundation |
Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
|
CN105254646A
(zh)
*
|
2014-05-28 |
2016-01-20 |
上海博邦医药科技有限公司 |
一种制备依维莫司的方法
|
JP2017518307A
(ja)
|
2014-06-02 |
2017-07-06 |
チルドレンズ メディカル センター コーポレーション |
免疫調節のための方法および組成物
|
RU2751660C2
(ru)
|
2014-07-21 |
2021-07-15 |
Новартис Аг |
Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
EP3660042B1
(de)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
T-zellen mit teilmengenoptimierten chimären antigenrezeptoren
|
WO2016020664A1
(en)
*
|
2014-08-04 |
2016-02-11 |
Cipla Limited |
Process for the synthesis of everolimus and intermediates thereof
|
CN112430250A
(zh)
|
2014-08-12 |
2021-03-02 |
莫纳什大学 |
定向淋巴的前药
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
PL3183268T3
(pl)
|
2014-08-19 |
2020-09-07 |
Novartis Ag |
Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
|
EP3524595B1
(de)
|
2014-08-28 |
2022-08-10 |
Eisai R&D Management Co., Ltd. |
Hochreines chinolinderivat und verfahren zur herstellung davon
|
EP3193902A4
(de)
|
2014-09-11 |
2018-03-28 |
The Regents of The University of California |
Mtorc1-inhibitoren
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
US10774388B2
(en)
|
2014-10-08 |
2020-09-15 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
US10143682B2
(en)
|
2014-10-28 |
2018-12-04 |
Koushi Yamaguchi |
Medicine for improving state of pregnancy, and use thereof
|
WO2016066608A1
(en)
|
2014-10-28 |
2016-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
|
EP3473253A1
(de)
|
2014-10-29 |
2019-04-24 |
University Of Maryland |
Verfahren zur behandlung altersbedingter symptome bei säugetieren und zusammensetzungen dafür
|
CN104478898A
(zh)
*
|
2014-11-18 |
2015-04-01 |
连云港恒运医药科技有限公司 |
依维莫司及其中间体的制备方法
|
WO2016135740A1
(en)
|
2015-02-23 |
2016-09-01 |
Natco Pharma Limited |
Process for preparing stable oral compositions of everolimus
|
AU2016224583B2
(en)
|
2015-02-25 |
2021-06-03 |
Eisai R&D Management Co., Ltd. |
Method for suppressing bitterness of quinoline derivative
|
DK3321265T3
(da)
|
2015-03-04 |
2020-06-08 |
Gilead Sciences Inc |
4,6-diamino-pyrido[3,2-d]pyrimidinforbindelser og deres udnyttelse som modulatorer af toll-lignende receptorer
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
CN107847491A
(zh)
|
2015-05-20 |
2018-03-27 |
诺华公司 |
依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
|
CN104892632B
(zh)
*
|
2015-06-03 |
2017-12-26 |
道中道(菏泽)制药有限公司 |
一种晶体形式的依维莫司及其制备方法
|
MX2017015896A
(es)
|
2015-06-16 |
2018-08-09 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
EP3109250A1
(de)
|
2015-06-23 |
2016-12-28 |
Synbias Pharma AG |
Verfahren zur synthese von rapamycinderivaten
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
PL3307322T3
(pl)
|
2015-09-04 |
2021-07-05 |
Primatope Therapeutics Inc. |
Humanizowane przeciwciała anty-cd40 i ich zastosowania
|
EP3347340A4
(de)
|
2015-09-08 |
2019-01-23 |
Monash University |
Lymphenleitungsprodrugs
|
WO2017081624A1
(en)
|
2015-11-11 |
2017-05-18 |
Novartis Ag |
Uses of myostatin antagonists, combinations containing them and uses thereof
|
CN105566348A
(zh)
*
|
2015-12-31 |
2016-05-11 |
哈药集团技术中心 |
一种依维莫司的制备方法
|
WO2017190145A1
(en)
|
2016-04-29 |
2017-11-02 |
Icahn School Of Medicine At Mount Sinai |
Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
|
US20190290631A1
(en)
|
2016-05-27 |
2019-09-26 |
Nippon Kayaku Kabushiki Kaisha |
Pharmaceutical composition comprising rapamycin or derivative thereof
|
CN109641947B
(zh)
|
2016-07-20 |
2023-04-14 |
犹他大学研究基金会 |
Cd229 car t细胞及其使用方法
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
MA46093A
(fr)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Composés modulateurs du recepteur de type toll
|
RU2019113504A
(ru)
|
2016-10-07 |
2020-11-09 |
Новартис Аг |
Химерные антигенные рецепторы для лечения рака
|
WO2018096402A1
(en)
|
2016-11-23 |
2018-05-31 |
Novartis Ag |
Methods of enhancing immune response with everolimus, dactolisib or both
|
EP3548894B1
(de)
|
2016-12-02 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur diagnose eines nierenzellkarzinoms
|
PE20191207A1
(es)
|
2016-12-22 |
2019-09-10 |
Amgen Inc |
Benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibidores de kras g12c para tratar el cancer de pulmon, pancreatico o colorrectal
|
GB201701087D0
(en)
|
2017-01-23 |
2017-03-08 |
Univ Leuven Kath |
Novel prodrugs of mizoribine
|
CA3053108A1
(en)
*
|
2017-02-10 |
2018-08-16 |
Mount Tam Therapeutics, Inc. |
Rapamycin analog
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
ES2871499T3
(es)
|
2017-05-15 |
2021-10-29 |
Bard Inc C R |
Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
WO2019002168A1
(en)
|
2017-06-26 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING OLMSTED SYNDROME
|
EP3652306A1
(de)
|
2017-07-13 |
2020-05-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur erhöhung der expansion und der immunosuppressiven kapazität einer population von cd8+cd45rclow/-tregs
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
IL272512B
(en)
|
2017-09-08 |
2022-07-01 |
Amgen Inc |
kras g12c inhibitors and methods of using them
|
AR112834A1
(es)
|
2017-09-26 |
2019-12-18 |
Novartis Ag |
Derivados de rapamicina
|
CN108047265A
(zh)
*
|
2017-11-24 |
2018-05-18 |
成都海创药业有限公司 |
一种依维莫司中间体的制备纯化方法
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
PL3788049T3
(pl)
|
2018-05-01 |
2023-06-19 |
Revolution Medicines, Inc. |
Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR
|
SG11202010560QA
(en)
|
2018-05-01 |
2020-11-27 |
Revolution Medicines Inc |
C26-linked rapamycin analogs as mtor inhibitors
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
JP7266043B2
(ja)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
US11045484B2
(en)
|
2018-05-04 |
2021-06-29 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
JP2021531061A
(ja)
|
2018-05-22 |
2021-11-18 |
インターフェース バイオロジクス,インコーポレーテッド |
薬物を脈管壁に送達するための組成物及び方法
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
CA3098885A1
(en)
|
2018-06-01 |
2019-12-05 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
JP7357644B2
(ja)
|
2018-06-11 |
2023-10-06 |
アムジエン・インコーポレーテツド |
がんを処置するためのkras g12c阻害剤
|
AU2019336588B2
(en)
|
2018-06-12 |
2022-07-28 |
Amgen Inc. |
KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
CN108676014A
(zh)
*
|
2018-06-15 |
2018-10-19 |
国药集团川抗制药有限公司 |
纯化依维莫司中间体的方法以及制备依维莫司的方法
|
CA3107352A1
(en)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
CA3107349A1
(en)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
US20220047567A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
JP7431226B2
(ja)
|
2018-10-05 |
2024-02-14 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ及びエベロリムスを含む併用療法のためのバイオマーカー
|
CN113226389B
(zh)
|
2018-11-14 |
2022-11-08 |
乐通公司 |
在经改性设备表面上具有药物洗脱涂层的医疗设备
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
JP7454572B2
(ja)
|
2018-11-19 |
2024-03-22 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤及びその使用方法
|
AU2019404576A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
MA54547A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
|
CN113226473A
(zh)
|
2018-12-20 |
2021-08-06 |
美国安进公司 |
Kif18a抑制剂
|
EP3897855B1
(de)
|
2018-12-20 |
2023-06-07 |
Amgen Inc. |
Kif18a-inhibitoren
|
SG11202106635WA
(en)
|
2018-12-21 |
2021-07-29 |
Daiichi Sankyo Co Ltd |
Combination of antibody-drug conjugate and kinase inhibitor
|
JP7061236B2
(ja)
*
|
2019-01-22 |
2022-04-27 |
エオビアン ファーマシューティカルズ, インコーポレイテッド |
Mtorcモジュレーターおよびその使用
|
SG11202109422WA
(en)
|
2019-03-01 |
2021-09-29 |
Revolution Medicines Inc |
Bicyclic heterocyclyl compounds and uses thereof
|
MX2021010319A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos biciclicos de heteroarilo y usos de estos.
|
EP3952937A1
(de)
|
2019-04-08 |
2022-02-16 |
Bard Peripheral Vascular, Inc. |
Medizinische vorrichtung mit wirkstofffreisetzender beschichtung auf modifizierter vorrichtungsoberfläche
|
JP2022526671A
(ja)
|
2019-04-11 |
2022-05-25 |
エンクリアー セラピーズ, インク. |
脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
AU2020280024A1
(en)
|
2019-05-21 |
2021-12-09 |
Amgen Inc. |
Solid state forms
|
TW202115056A
(zh)
|
2019-06-28 |
2021-04-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
WO2021001743A1
(en)
|
2019-07-02 |
2021-01-07 |
Effector Therapeutics, Inc. |
Translation inhibitors and uses thereof
|
WO2021026100A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Pyridine derivatives as kif18a inhibitors
|
JP2022542967A
(ja)
|
2019-08-02 |
2022-10-07 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CA3147272A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
WO2021055728A1
(en)
|
2019-09-18 |
2021-03-25 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
IL292438A
(en)
|
2019-10-28 |
2022-06-01 |
Merck Sharp & Dohme |
Small molecules that inhibit the g12c mutant of kras
|
JP2023515235A
(ja)
|
2019-10-31 |
2023-04-12 |
大鵬薬品工業株式会社 |
4-アミノブタ-2-エンアミド誘導体及びその塩
|
CN115873067A
(zh)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
Ras抑制剂
|
EP4054719A1
(de)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras-inhibitoren
|
PE20221277A1
(es)
|
2019-11-04 |
2022-09-05 |
Revolution Medicines Inc |
Inhibidores de ras
|
CA3156359A1
(en)
|
2019-11-08 |
2021-05-14 |
Adrian Liam Gill |
Bicyclic heteroaryl compounds and uses thereof
|
TW202132296A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
TW202132271A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ras阻害剤及びその使用
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
JP2023509701A
(ja)
|
2020-01-07 |
2023-03-09 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Shp2阻害剤投薬およびがんを処置する方法
|
WO2021159021A1
(en)
|
2020-02-05 |
2021-08-12 |
Puretech Lyt, Inc. |
Lipid prodrugs of neurosteroids
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
JP7373664B2
(ja)
|
2020-07-15 |
2023-11-02 |
大鵬薬品工業株式会社 |
腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
CR20230165A
(es)
|
2020-09-15 |
2023-06-02 |
Revolution Medicines Inc |
Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
US11859021B2
(en)
|
2021-03-19 |
2024-01-02 |
Icahn School Of Medicine At Mount Sinai |
Compounds for regulating trained immunity, and their methods of use
|
AU2022268962A1
(en)
|
2021-05-05 |
2023-12-14 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
CA3217393A1
(en)
|
2021-05-05 |
2022-11-10 |
Elena S. Koltun |
Ras inhibitors
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ras阻害剤及びその使用
|
EP4347041A1
(de)
|
2021-05-28 |
2024-04-10 |
Taiho Pharmaceutical Co., Ltd. |
Kleinmolekülige inhibitoren von kras-mutierten proteinen
|
JP2024529341A
(ja)
|
2021-07-15 |
2024-08-06 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
粒子が付着している細胞に関連する組成物および方法
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024100236A1
(en)
|
2022-11-11 |
2024-05-16 |
Astrazeneca Ab |
Combination therapies for the treatment of cancer
|
CN116813641A
(zh)
*
|
2023-06-09 |
2023-09-29 |
杭州华东医药集团康润制药有限公司 |
一种依维莫司的制备方法
|